CordenPharma Plans €900 Million Investment to Enhance Peptide Platform in the USA and Europe
Tuesday, July 16, 2024
CordenPharma has recently announced its largest strategic investment, totaling around €900 million over the next three years, aimed at expanding its Peptide technology platform. This initiative includes significant expansions in both the US and Europe, focusing on upgrading existing facilities and constructing new ones that meet rigorous pharmaceutical industry standards, including Biologics License Application (BLA) requirements.
In the US, CordenPharma plans to expand its Peptide manufacturing capacity at its Colorado site by building a new large-scale facility and increasing production in its current facilities. This expansion is driven by rising demand for Glucagon-like Peptide 1 (GLP-1) agonists used in treatments for Diabetes and Obesity. The company has secured several long-term contracts totaling approximately €3 billion, with potential for further growth.
In Europe, CordenPharma will construct a state-of-the-art greenfield facility to expand its Peptide production capabilities. This new facility, strategically located within CordenPharma's existing network, will support customers from early clinical development through to commercial manufacturing.
Acquired by Astorg, a prominent Pan-European private equity firm, in 2022, CordenPharma aims to achieve around €1 billion in sales from its Peptide Platform and €1.8 billion in total group revenue by 2028. The expansions will integrate seamlessly into CordenPharma's existing cGMP manufacturing facilities, enhancing its ability to offer comprehensive services from APIs to Drug Products. This move highlights CordenPharma's commitment to supporting innovators and securing supply chains for transformative medicines.
CordenPharma Group, emphasized these investments as crucial for strengthening support for innovators and meeting patient needs. He highlighted the trust placed by customers in CordenPharma's expertise and the strategic vision of Astorg in positioning CordenPharma as a leader in complex modalities like Peptides.
The expansions underscore Astorg's confidence in CordenPharma's operational excellence and growth potential in pharmaceutical services, particularly in peptides, where the company aims to solidify its leadership with expanded manufacturing capabilities and enhanced performance in large-scale production.
Overall, CordenPharma's strategic investments and expansions demonstrate its commitment to innovation and its role as a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry.
Source: prnewswire.com
